换一批Use of angiotensin converting enzyme inhibitors is associated with reduced risk of late bladder toxicity following radiotherapy for prostate cancer.
第一作者：
Sarah L,Kerns
第一单位：
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States. Electronic address: sarah_kerns@urmc.rochester.edu.
作者：
Sarah L,Kerns [1]
;
Ashley,Amidon Morlang [2]
;
Sharon M,Lee [2]
;
Derick R,Peterson [3]
;
Brian,Marples [2]
;
Hong,Zhang [2]
;
Kevin,Bylund [2]
;
Doug,Rosenzweig [2]
;
William,Hall [4]
;
Kim,De Ruyck [5]
;
Barry S,Rosenstein [6]
;
Richard G,Stock [7]
;
Antonio,Gómez-Caamaño [8]
;
Ana,Vega [9]
;
Paloma,Sosa-Fajardo [10]
;
Begoña,Taboada-Valladares [8]
;
Miguel E,Aguado-Barrera [11]
;
Chris,Parker [12]
;
Liv,Veldeman [5]
;
Valérie,Fonteyne [5]
;
Renée,Bultijnck [5]
;
Christopher J,Talbot [13]
;
R Paul,Symonds [13]
;
Kerstie,Johnson [13]
;
Tim,Rattay [13]
;
Adam,Webb [14]
;
Maarten,Lambrecht [15]
;
Dirk,de Ruysscher [16]
;
Ben,Vanneste [16]
;
Ananya,Choudhury [17]
;
Rebecca M,Elliott [17]
;
Elena,Sperk [18]
;
Carsten,Herskind [18]
;
Marlon R,Veldwijk [18]
;
Tiziana,Rancati [19]
;
Barbara,Avuzzi [20]
;
Riccardo,Valdagni [21]
;
David,Azria [22]
;
Marie-Pierre,Farcy Jacquet [23]
;
Jenny,Chang-Claude [24]
;
Petra,Seibold [25]
;
Catharine,West [17]
;
Michelle,Janelsins [26]
;
Yuhchyau,Chen [2]
;
Edward,Messing [27]
;
Gary,Morrow [26]
;
REQUITE Consortium
作者单位：
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States. Electronic address: sarah_kerns@urmc.rochester.edu.
[1]
Department of Radiation Oncology, University of Rochester Medical Center, Rochester, United States.
[2]
Department of Biostatistics and Computational Biology, University of Rochester Medical Center, Rochester, United States.
[3]
Department of Radiation Oncology, Medical College of Wisconsin, Milwaukee, United States.
[4]
Department of Radiation Oncology, Ghent University Hospital and Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
[5]
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States; Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, United States.
[6]
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, United States.
[7]
Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain.
[8]
Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Fundación Pública Galega de Medicina Xenómica-Servizo Galego de Saude (SERGAS), Santiago de Compostela, Spain; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER), Santiago de Compostela, Spain.
[9]
Department of Radiation Oncology, Complexo Hospitalario Universitario de Santiago, SERGAS, Santiago de Compostela, Spain; Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Fundación Pública Galega de Medicina Xenómica-Servizo Galego de Saude (SERGAS), Santiago de Compostela, Spain.
[10]
Instituto de Investigación Sanitaria de Santiago de Compostela (IDIS), Santiago de Compostela, Spain; Fundación Pública Galega de Medicina Xenómica-Servizo Galego de Saude (SERGAS), Santiago de Compostela, Spain.
[11]
Department of Uro-oncology, The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, Sutton, United Kingdom.
[12]
Leicester Cancer Research Centre, University of Leicester, United Kingdom.
[13]
Department of Genetics and Genome Biology, University of Leicester, United Kingdom.
[14]
KU Leuven, Radiation Oncology, Leuven, Belgium.
[15]
KU Leuven, Radiation Oncology, Leuven, Belgium; Maastricht University Medical Center, Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht, the Netherlands.
[16]
Division of Cancer Sciences, the University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester, the Netherlands.
[17]
Department of Radiation Oncology, Universitätsmedizin Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
[18]
Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
[19]
Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
[20]
Prostate Cancer Program, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Radiation Oncology 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Department of Oncology and Hemato-oncology, Università degli Studi di Milano, Milan, Italy.
[21]
Department of Radiation Oncology, Montpellier Cancer Institute, Université Montpellier, Inserm U1194, France.
[22]
ICG Cancer Institute, Centre Hospitalier Universitaire de Nîmes, Nimes, France.
[23]
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Cancer Epidemiology Group, University Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, Germany.
[24]
Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
[25]
Department of Surgery, University of Rochester Medical Center, Rochester, United States.
[26]
Department of Urology, University of Rochester Medical Center, Rochester, United States.
[27]
医学主题词
血管紧张素转换酶抑制药(Angiotensin-Converting Enzyme Inhibitors);全基因组关联研究(Genome-Wide Association Study);人类(Humans);男(雄)性(Male);前列腺(Prostate);前列腺肿瘤(Prostatic Neoplasms);膀胱(Urinary Bladder)
DOI
10.1016/j.radonc.2022.01.014
PMID
35077710
发布时间
2025-05-30
- 浏览0
Radiotherapy and oncology
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文
